✦ LIBER ✦

Eicosapentaenoic Acid Supplementation for Chronic Hepatitis C Patients During Combination Therapy of Pegylated Interferon α-2b and Ribavirin

✍ Scribed by Aiko Kawashima; Ikuyo Tsukamoto; Tomoko Koyabu; Yasuko Murakami; Takayo Kawakami; Naoko Kakibuchi; Kouichi Takaguchi; Keiji Kita; Misako Okita

Book ID: 107487933
Publisher: Springer-Verlag
Year: 2008
Tongue: English
Weight: 255 KB
Volume: 43
Category: Article
ISSN: 0024-4201
DOI: 10.1007/s11745-008-3157-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Leukocyte interferon-α and ribavirin for

Leukocyte interferon-α and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon

✍ Luigi E. Adinolfi; Emanuele Durante-Mangoni; Marta Salzillo; Aldo Marrone; Marie 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 161 KB

Pegylated interferon α-2b plus ribavirin

Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients

✍ Esther Voigt; Christian Schulz; Gerd Klausen; Joerg Goelz; Stefan Mauss; Guenthe 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Adequate timing of ribavirin reduction i

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C

✍ Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Ma 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 171 KB

Efficacy of combined pegylated interfero

Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C

✍ Jorge-Shmuel Delgado; Yael Baumfeld; Victor Novack; Shulamit Monitin; Alan Jotko 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 217 KB

Limitation of combination therapy of int

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C

✍ Yoshiaki Iwasaki; Hiroshi Ikeda; Yasuyuki Araki; Toshiya Osawa; Keiji Kita; Masa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy a

Efficacy of re-treatment with pegylated

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

✍ Tsugiko Oze; Naoki Hiramatsu; Takayuki Yakushijin; Kiyoshi Mochizuki; Masahide O 📂 Article 📅 2011 🏛 Springer Japan 🌐 English ⚖ 297 KB